Mustang Bio Announces Pricing of Public Offering of Common Stock

Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, announced on April 30th the pricing of its previously announced underwritten public offering. Mustang is offering 6,875,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $4.00 per share. In connection with the offering, Mustang has also granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock offered in the public offering, at the same public offering price per share, to cover over-allotments, if any. Cantor Fitzgerald & Co. is acting as lead book running manager for the offering.  Oppenheimer & Co. Inc. is acting as book running manager, and H.C. Wainwright & Co. and Roth Capital Partners are acting as co-managers for the offering. The Company expects to receive gross proceeds from the offering, excluding the exercise of the over-allotment option, if any, of $27.5 million, excluding underwriting discounts and commissions and other offering-related expenses. Assuming the full exercise of the over-allotment option, gross proceeds would be $31.6 million.

For further information see Fortress Biotech (